The Ibr‐7 derivative of ibrutinib exhibits enhanced cytotoxicity against non‐small cell lung cancer cells via targeting of mTORC1/S6 signaling

Ibrutinib is a small molecule drug that targets Bruton's tyrosine kinase in B‐cell malignancies and is highly efficient at killing mantle cell lymphoma and chronic lymphocytic leukemia. However, the anti‐cancer activity of ibrutinib against solid tumors, such as non‐small cell lung cancer (NSCL...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Bo, Wang, Linling, Zhang, Qi, Yan, Youyou, Jiang, Hong, Hu, Runlei, Zhou, Xinglu, Liu, Xingguo, Feng, Jianguo, Lin, Nengming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441926/
https://www.ncbi.nlm.nih.gov/pubmed/30663221
http://dx.doi.org/10.1002/1878-0261.12454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441926/
https://www.ncbi.nlm.nih.gov/pubmed/30663221
http://dx.doi.org/10.1002/1878-0261.12454

Ejemplares similares